HRMY Q4 2023 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168M+31.3% YoY

Gross Profit

$125M74.4% margin

Operating Income

$40M23.9% margin

Net Income

$27M15.8% margin

EPS (Diluted)

$0.45

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$77M

Free Cash Flow

$77M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$811M

Total Liabilities

$344M

Stockholders' Equity

$467M

Cash & Equivalents

$312M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$128M	+31.3%
Gross Profit	$125M	$101M	+23.5%
Operating Income	$40M	$48M	-15.6%
Net Income	$27M	$49M	-45.2%